Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

PubWeight™: 1.11‹?› | Rank: Top 10%

🔗 View Article (PMC 3956363)

Published in Neuro Oncol on January 30, 2014

Authors

Bing Liao1, Sheetal Shroff, Carlos Kamiya-Matsuoka, Sudhakar Tummala

Author Affiliations

1: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (B.L., S.S., C.K.-M., S.T.); Department of Neurology, The University of Texas Medical Branch, Galveston, Texas (B.L., S.S., C.K.-M.).

Articles cited by this

Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol (2010) 3.10

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol (2011) 1.37

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci (2008) 1.23

Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci (2009) 1.17

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res (2012) 1.08

Interleukin-6 and melanoma. Melanoma Res (2012) 1.07

Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol (2000) 0.91

Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91

Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90

Articles by these authors

NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw (2009) 1.35

Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol (2015) 0.99

F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med (2011) 0.95

Intraoperative magnetic resonance imaging-guided tractography with integrated monopolar subcortical functional mapping for resection of brain tumors. Clinical article. J Neurosurg (2010) 0.86

Subcortical injury is an independent predictor of worsening neurological deficits following awake craniotomy procedures. Neurosurgery (2013) 0.86

Preoperative imaging to predict intraoperative changes in tumor-to-corticospinal tract distance: an analysis of 45 cases using high-field intraoperative magnetic resonance imaging. Neurosurgery (2014) 0.83

Utilization of intraoperative motor mapping in glioma surgery with high-field intraoperative magnetic resonance imaging. Stereotact Funct Neurosurg (2010) 0.82

Guillain-Barré syndrome and glioblastoma. J Neurooncol (2010) 0.79

Awake craniotomy for gliomas in a high-field intraoperative magnetic resonance imaging suite: analysis of 42 cases. J Neurosurg (2014) 0.78

Simultaneous use of functional tractography, neuronavigation-integrated subcortical white matter stimulation and intraoperative magnetic resonance imaging in glioma surgery: technical note. Stereotact Funct Neurosurg (2009) 0.77

Herpes myelitis after thoracic spine surgery. J Neurosurg Spine (2013) 0.75

Gradient competition anisotropy for centerline extraction and segmentation of spinal cords. Inf Process Med Imaging (2013) 0.75

Posterior reversible encephalopathy syndrome: more than meets the eye. J Clin Oncol (2013) 0.75

The path forward for anti-programmed death-1 therapy in gliomas. Curr Opin Neurol (2019) 0.75

Postoperative varicella-zoster virus myelopathy and dissemination. Arch Neurol (2011) 0.75

Progressive multifocal leukoencephalopathy in a patient with glioblastoma. J Neurooncol (2010) 0.75